Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference

SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference.

Nautilus’ management is scheduled to participate in a fireside chat on Wednesday, November 13, 2024, at 9:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact
[email protected]

Investor Contact
[email protected]

You May Also Be Interested In

• RCI BANQUE : PLACEMENT OF A 890.2 MILLION EURO SECURITISATION BACKED BY SPANISH AUTO LOANS
• Phemex Reinforces Institutional Safety with 100%+ September Reserves
• Spark Energy Minerals Appoints Marina Fagundes de Freitas to its Board of Directors